1.18
3.51%
0.04
After Hours:
1.23
0.05
+4.24%
Nektar Therapeutics Stock (NKTR) Financials Data
Income Statement
Quarterly
*All numbers in millions
Period End Date | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
Period Length | 3 Months | 3 Months | 3 Months | 3 Months | 3 Months |
Revenues |
9.40%
21.64
|
23.89 | 24.14 | 20.50 | 21.59 |
Cost Of Revenue |
17.18%
8.534
|
7.283 | 12.43 | 6.994 | 7.06 |
Gross Profit |
21.06%
13.11
|
16.60 | 11.71 | 13.51 | 14.53 |
Operating Expenses
|
3.15%
48.53
|
50.11 | 56.58 | 64.10 | 149.24 |
Benefits Costs and Expenses |
11.39%
58.48
|
65.99 | 70.04 | 71.67 | 158.68 |
Costs And Expenses |
0.57%
57.07
|
57.40 | 69.01 | 71.10 | 156.30 |
Depreciation and Amortization |
2.72%
1.607
|
1.652 | 1.695 | 2.166 | 2.302 |
Operating Income/Loss |
5.72%
-35.43
|
-33.51 | -44.86 | -50.60 | -134.71 |
Nonoperating Income/Loss |
83.60%
-1.41
|
-8.597 | -1.034 | -0.57 | -2.371 |
Income/Loss From Continuing Operations Before Tax |
12.52%
-36.84
|
-42.11 | -45.90 | -51.17 | -137.08 |
Income Tax Expense/Benefit, Deferred |
102.22%
-0.038
|
1.714 | -0.015 | -0.027 | -1.812 |
Income Tax Expense/Benefit |
20.69%
-0.035
|
-0.029 | -0.061 | -0.047 | -0.063 |
Income/Loss From Continuing Operations After Tax |
12.54%
-36.80
|
-42.08 | -45.84 | -51.12 | -137.02 |
Net Income/Loss
|
12.54%
-36.80
|
-42.08 | -45.84 | -51.12 | -137.02 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
Basic Average Shares |
55,542%
194.75
|
0.35 | 190.41 | 189.66 | 188.88 |
Diluted Average Shares |
55,542%
194.75
|
0.35 | 190.41 | 189.66 | 188.88 |
Basic Earnings Per Share |
13.64%
-0.19
|
-0.22 | -0.24 | -0.27 | -0.73 |
Diluted Earnings Per Share |
13.64%
-0.19
|
-0.22 | -0.24 | -0.27 | -0.73 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):